Marina Onda
Inzai, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: April 09, 2025
24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: March 18, 2025
Real-world outcomes of lebrikizumab treatment for upadacitinib-refractory atopic dermatitis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 01, 2025
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: February 20, 2025
Long-term maintenance of responses to bimekizumab treatment in moderate-to-severe psoriasis: A real-world comparison of Q4W versus Q8W dosing or bio-naïve versus bio-switched patients.
Journal: The Journal of dermatology
Published: January 14, 2025
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.
Journal: European journal of dermatology : EJD
Published: November 26, 2024
Real-world 52-week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index.
Journal: The Journal of dermatology
Published: November 07, 2024
Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: October 03, 2024
Predictive factors for responders to deucravacitinib treatment in patients with psoriasis.
Journal: The Journal of dermatology
Published: September 08, 2024
Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study.
Journal: Clinical and experimental dermatology
Published: May 24, 2024
Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study.
Journal: The Journal of dermatology
Published: May 17, 2024
Metastatic iris tumor.
Journal: QJM : monthly journal of the Association of Physicians
Published: April 18, 2023
Showing 1-12 of 12
Last Updated: 09/26/2026